Search
Displaying 421–430 of 1066 results
-
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
Research NewsThe company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
Live Stream: XLRP-Patient Focused Drug Development
The live meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
XLRP-Patient Focused Drug Development
The goal of the June 7th meeting will be to educate FDA staff and other key stakeholders such as biotech and pharmaceutical companies about what it is like to live with XLRP, with perspectives from both affected individuals as well as caregivers and family members of affected individuals.
-
The Karen And Basil Petrou Legacy Education Initiative
The Basil and Karen Petrou Education Initiative is born of the Foundation’s commitment to helping individuals ensure their estates do the best they can for their loved ones and the causes they care about. Debuting this year, the program will offer ongoing resources to help individuals and families explore and learn about end-of-life plans and strategies.
-
“Great Vision Does Not Require Great Sight”
Beacon StoriesKenyetta has worked to help others through the nonprofit sector for over 25 years, despite being diagnosed with Stargardt disease at the age of 31. Kenyetta is now the chief operating officer of REACH Riverside Development Corporation and has been recognized for her career achievements by many.
-
Webinar for the X-Linked Retinitis Pigmentosa (XLRP) Community
Research NewsThe Foundation Fighting Blindness recently held a webinar to provide details about an upcoming Externally-Led Patient Focused Drug Development (EL-PFDD) meeting for XLRP, and to provide background information about the Food and Drug Administration’s (FDA) drug review process.
-
Foundation Summit Highlights Robust Growth in Commercial Development for Retinal Disease Therapies
Foundation NewsThe Foundation’s Investing in Cures Summit (ICS), held on April 2, 2022, in Half Moon Bay, California, convened 175 researchers, industry executives, and constituents to present and discuss the expanding and accelerating commercial development of emerging therapies for retinal degenerative diseases.
-
“The Only Disability is a Bad Attitude”
Beacon StoriesBorn with LCA, Anthony began wrestling in the seventh grade, continued through high school, and eventually became the subject of a documentary about his life as a blind wrestler. He then received a life-changing call from the United States Olympics Committee, asking him to compete on the Paralympic Judo Team.
-
Drug for Alcohol Abuse May Restore Vision for People with Retinal Diseases
Research NewsThe drug holds promise for enabling retinal-disease patients to get more vision from remaining photoreceptors
-
Beacon Stories
In her own words, Bari shares her perspective with having a father and brother affected with retinitis pigmentosa and how she’s now helping to make a difference to end blinding diseases.
